Optimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool

Inclusion Criteria:

• Patients diagnosed with Major Depressive Disorder as certified by a SCID 5 (Structured Clinical Interview for DSM-5) for DSM-S for adults and K-SADS-PL-DSM 5 (Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetimefor DSM 5) for adolescents.

• Currently experiencing a major depressive episode with a HAM-D (Hamilton Depression)score of 18 or greater, or alternatively, a MADRS (Montgomery-Asberg DepressionRating Scale) score of 18 or greater.

• About to start a new antidepressant.

• Not concurrently starting a new psychotropic medication.

• Age 14-50 years.

• Able to use mobile devices (smart phone, tablet).

• Willingness to provide written informed consent to participate.

Exclusion Criteria:

• Intellectual disability.

• Neurological disease (multiple sclerosis, severe neurocognitive disorder, epilepsy).

• Current psychotic disorder or mood disorder with psychotic features.

• Primary diagnosis of alcohol or substance use disorder (DSM-5).

• Patients who started concomitant psychotropic medications less than one week ago.

• Active, ongoing inflammatory diseases (such as rheumatoid arthritis and rheumaticpolymyalgia). or severe and unstable physical illness (such as recent myocardialinfarction).

• A history of hepatitis B or C, human immunodeficiency virus, or evidence of activetuberculosis infection or any active systemic infection within 2 weeks prior to thestart of the study.

• Use of antibiotics or other medications that may have affected the composition ofthe microbiota during the 30 days prior to baseline.

• Pregnancy and lactation.